Home » Topics » BioWorld Science, Infection

BioWorld Science, Infection
RSS

Arrowhead reports phase II and preclinical results for siRNA therapies targeting HBV

Sep. 29, 2015

Viekirax approved for treatment of genotype 1 HCV infection in Japan

Sep. 28, 2015

Sideromycin-based antibiotics yield positive results against Gram-negative bacteria

Sep. 28, 2015

VivaGel BV approved in E.U. for bacterial vaginosis

Sep. 25, 2015

Nanoglobular antimicrobial shows in vivo activity against B. cepacea

Sep. 25, 2015

Antibacterial compounds in early development at Actelion Pharmaceuticals

Sep. 23, 2015

Nagoya City University divulges antimalaria agents

Sep. 23, 2015

BTZ-169 active in tuberculosis model, phase I study planned

Sep. 23, 2015

Roche reports compounds for the treatment of hepatitis B

Sep. 22, 2015

Gilead reports topline results from four phase III studies of sofosbuvir/velpatasvir for HCV

Sep. 22, 2015

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 5, 2026.
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 3, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...